Sartorius Stedim Biotech SA banner

Sartorius Stedim Biotech SA
PAR:DIM

Watchlist Manager
Sartorius Stedim Biotech SA Logo
Sartorius Stedim Biotech SA
PAR:DIM
Watchlist
Price: 151 EUR -3.7%
Market Cap: €14.7B

P/E

54.8
Current
27%
Cheaper
vs 3-y average of 75.3

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
54.8
=
Market Cap
€15.8B
/
Net Income
€268.3m

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
54.8
=
Market Cap
€15.8B
/
Net Income
€268.3m

Valuation Scenarios

Sartorius Stedim Biotech SA is trading below its 3-year average

If P/E returns to its 3-Year Average (75.3), the stock would be worth €207.7 (38% upside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-72%
Maximum Upside
+43%
Average Upside
11%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple 54.8 €151
0%
3-Year Average 75.3 €207.7
+38%
5-Year Average 73.8 €203.51
+35%
Industry Average 78.5 €216.37
+43%
Country Average 15.5 €42.72
-72%

Forward P/E
Today’s price vs future net income

Today's Market Cap Net Income Forward P/E
€15.8B
/
Apr 2026
€268.3m
=
54.8
Current
€15.8B
/
Dec 2026
€501.2m
=
31.5
Forward
€15.8B
/
Dec 2027
€599.3m
=
26.3
Forward
€15.8B
/
Dec 2028
€705m
=
22.4
Forward
€15.8B
/
Dec 2029
€863m
=
18.3
Forward
€15.8B
/
Dec 2030
€982.7m
=
16.1
Forward
€15.8B
/
Dec 2031
€1.1B
=
14.1
Forward
€15.8B
/
Dec 2032
€1.2B
=
12.7
Forward
€15.8B
/
Dec 2033
€1.4B
=
11.4
Forward

Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.

Market Distribution

Higher than 90% of companies in France
Percentile
90th
Based on 1 397 companies
90th percentile
54.8
Low
0.2 — 11
Typical Range
11 — 26.8
High
26.8 —
Distribution Statistics
France
Min 0.2
30th Percentile 11
Median 15.5
70th Percentile 26.8
Max 3 102.9

Sartorius Stedim Biotech SA
Glance View

Sartorius Stedim Biotech SA has been weaving the intricate threads of biotechnology innovation into a fabric of global influence and success. Established as a pivotal player in the biopharmaceutical industry, Sartorius Stedim Biotech has carved out a niche by offering sophisticated products and solutions that cater to the unique needs of biopharmaceutical manufacturers. The company’s portfolio is a testament to the fusion of scientific ingenuity and relentless pursuit of quality. Spanning filtration and purification solutions, fermentation equipment, and fluid management systems, their offerings ensure that complex biological drugs, including vaccines and monoclonal antibodies, are produced efficiently and safely. Sartorius Stedim Biotech’s endeavor is not just about supplying equipment; it’s about providing integrated solutions that optimize the entire production process, ensuring consistency, scalability, and compliance in industries bound by strict regulatory oversight. The company generated revenue through its comprehensive range of products and services that address every step of the biomanufacturing process. Their business model hinges on fostering long-term relationships with clients by offering tailored solutions that enhance productivity and reduce time-to-market for new therapies. Beyond direct sales of high-value equipment, Sartorius Stedim Biotech also capitalizes on recurring revenue streams generated from consumables and maintenance services essential for the ongoing operation of their systems. By continuously innovating and expanding its product lines, the company stays at the forefront of technological advancements, enabling clients to tackle the ever-evolving challenges of bioproduction. As the global biopharmaceutical industry surges forward, driven by increasing demand for biologics, Sartorius Stedim Biotech remains poised to maintain its role as an indispensable ally to firms dedicated to transforming the health landscape through revolutionary therapies.

DIM Intrinsic Value
138.44 EUR
Overvaluation 8%
Intrinsic Value
Price €151
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett